Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have been given a consensus rating of "Buy" by the six brokerages that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued a report on the stock in the last year is $21.00.

ARTV has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a "buy" rating and a $20.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth about $216,000. BNP Paribas Financial Markets grew its position in shares of Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock valued at $100,000 after acquiring an additional 7,151 shares during the period. Northern Trust Corp grew its position in shares of Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company's stock valued at $1,180,000 after acquiring an additional 4,335 shares during the period. Barclays PLC grew its position in shares of Artiva Biotherapeutics by 23.2% during the 4th quarter. Barclays PLC now owns 24,161 shares of the company's stock valued at $244,000 after acquiring an additional 4,545 shares during the period. Finally, Wells Fargo & Company MN grew its position in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock valued at $87,000 after acquiring an additional 3,361 shares during the period.

Artiva Biotherapeutics Stock Performance

ARTV stock traded down $0.02 during midday trading on Tuesday, reaching $3.77. The stock had a trading volume of 69,573 shares, compared to its average volume of 79,349. The firm has a fifty day simple moving average of $7.46 and a two-hundred day simple moving average of $10.42. Artiva Biotherapeutics has a 52-week low of $3.37 and a 52-week high of $17.31.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.